日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors

利用PD-1阻断抑制布鲁顿酪氨酸激酶可以调节实体瘤中的T细胞活化。

Emily Schwarz ,Brooke Benner ,Robert Wesolowski ,Dionisia Quiroga ,Logan Good ,Steven H Sun ,Himanshu Savardekar ,Jianying Li ,Kyeong Joo Jung ,Megan C Duggan ,Gabriella Lapurga ,Jami Shaffer ,Luke Scarberry ,Bhavana Konda ,Claire Verschraegen ,Kari Kendra ,Manisha Shah ,Robert Rupert ,Paul Monk ,Hiral A Shah ,Anne M Noonan ,Kristin Bixel ,John Hays ,Lai Wei ,Xueliang Pan ,Gregory Behbehani ,Yang Hu ,Olivier Elemento ,Dongjun Chung ,Gang Xin ,Bradley W Blaser ,William E Carson 3rd

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq

利用超灵敏LC-FACSeq技术对急性髓系白血病细胞层级进行基因组分析

Caner Saygin ,Eileen Hu ,Pu Zhang ,Steven Sher ,Arletta Lozanski ,Tzyy-Jye Doong ,Deedra Nicolet ,Shelley Orwick ,Jadwiga Labanowska ,Jordan N Skinner ,Casey Cempre ,Tierney Kauffman ,Virginia M Goettl ,Nyla A Heerema ,Lynne Abruzzo ,Cecelia Miller ,Rosa Lapalombella ,Gregory Behbehani ,Alice S Mims ,Karilyn Larkin ,Nicole Grieselhuber ,Alison Walker ,Bhavana Bhatnagar ,Clara D Bloomfield ,John C Byrd ,Gerard Lozanski # ,James S Blachly #

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

口服 JAK2/FLT3 抑制剂帕克替尼联合化疗治疗 FLT3-ITD 阳性 AML 的临床前活性和 I 期试点研究

Jae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, Mitch Phelps, Alison R Walker, Alice S Mims, Sumithira Vasu, Gregory Behbehani, James Blachly, William Blum, Rebecca B Klisovic, John C Byrd, Ramiro Garzon, Sharyn D Baker, Bhavana Bhatnagar